Posted by Michael Wonder on 07 Jul 2021
Enzalutamide for men with hormone sensitive metastatic prostate cancer
7 July 2021 - NICE publishes final guidance on a new indication for Xtandi.
Enzalutamide, when used in combination with androgen deprivation therapy, is recommended within its marketing authorisation, as an option for the treatment of adults with hormone sensitive metastatic prostate cancer.
